NCT00294372 - Phase II Study on the Antiviral Activity and Safety of BILR 355 BS in HIV-1 Infected, NNRTI-treated Patients | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

February 28, 2006

Primary Completion Date

September 30, 2007

Conditions

HIV Infections

Interventions

DRUG

BILR 355 BS

DRUG

Placebo

Trial Locations (11)

Boehringer Ingelheim Investigational Site, Berlin

Boehringer Ingelheim Investigational Site, Bochum

Boehringer Ingelheim Investigational Site, Bonn

Boehringer Ingelheim Investigational Site, Erlangen

Boehringer Ingelheim Investigational Site, Frankfurt am Main

Boehringer Ingelheim Investigational Site, Hamburg

Boehringer Ingelheim Investigational Site, Hanover

Boehringer Ingelheim Investigational Site, Heidelberg

Boehringer Ingelheim Investigational Site, Mainz

Boehringer Ingelheim Investigational Site, München

Boehringer Ingelheim Investigational Site, Ulm